Immuneering Corporation Class A Common Stock (IMRX)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money and possess durable advantages. Immuneering is not yet that. It is a late-stage oncology company with a Phase 3 asset, IMM-1-104, and earlier-stage IMM-6-415, but the filed figures show no revenue and persistent losses. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$17.3M and diluted EPS was -$0.27. Fiscal Q1 2026, ended 2026-03-31, showed -$13.5M and -$0.21. Full-year FY2025, ended 2025-12-31, net income was -$56.0M, EPS -$1.27; FY2024, ended 2024-12-31, net income was -$61.0M, EPS -$2.04. Losses narrowed, but the company remains unprofitable. Trailing free cash flow is -$57.0M, a FairStock FCF yield of -24.7%. At a $3.56 close on 2026-10-13, market cap is $230.3M. FairStock ratios show P/E -3.83 and P/B 1.21, while ROE is -52.15% and ROCE -32.77%. The balance sheet has little leverage, D/E 0.02, and Altman Z-Score 10.94, but Piotroski F-Score is 0/9. There is no Lynch category because losses occurred in each of the last four years. A moat is absent until approvals, reimbursement, and commercial scale appear. The 52-week range is $3.55-$8.48, so the price sits at the low end. FairStock score 64/100 suggests some positive features, but no margin of safety is visible in earnings. I would wait for proof, not pay for hope.

In plain English: Immuneering is a small healthcare company trying to make new cancer medicines. It does not yet sell any products, so it has no revenue and has lost money every year. It has very little debt, but it spends a lot on research, and its stock price is near the lowest point of the past year. With no profits, the price is hard to judge on normal business numbers and looks more speculative than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer